GlassScriptPhysician profile
Krishnan Nair
NPI 1578518684
$760.56
in general payments reported to CMS, 2019-2025
14 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2024: $272 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $112.44 | 2019-2025 | |
| Lilly USA, LLC | $89.08 | 2024-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $88.63 | 2024-2025 | |
| Novo Nordisk INC | $84.78 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $70.14 | 2024-2025 | Evenity, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $69.27 | 2024-2025 | |
| Abbott Laboratories | $66.98 | 2024-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $50.03 | 2019-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $37.00 | 2019 | |
| Dynavax Technologies Corporation | $21.54 | 2024 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $20.99 | 2019 | |
| Cvrx, INC. | $18.13 | 2025 | Barostim Neo System |
| Glaxosmithkline, LLC. | $17.95 | 2025 | Trelegy Ellipta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishnan Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.